Completed PHASE3 INTERVENTIONAL NCT00335933

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia

Sponsor: Depomed

Conditions Neuralgia, Postherpetic

Interventions Gabapentin extended-release tablets

Updated 5 times since 2017 Last updated: Aug 1, 2007 Started: May 31, 2006 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00335933, this PHASE3 trial focuses on Neuralgia, Postherpetic and remains completed. Sponsored by Depomed, it has been updated 5 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Depomed

Data source: Depomed

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Austin, United States